Pharmacogenetics, pharmacogenomics, and individualized medicine
about
Genomics and the Nature of Behavioral and Social RiskDiscovery and validation of small-molecule heat-shock protein 90 inhibitors through multimodality molecular imaging in living subjectsPharmacometabolomics-aided Pharmacogenomics in Autoimmune DiseasePromise of personalized omics to precision medicineApplication of routine electronic health record databases for pharmacogenetic researchPharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision MedicineIndividualization of antiretroviral therapy--pharmacogenomic aspectCost-Effectiveness of Pharmacogenomic and Pharmacogenetic Test-Guided Personalized Therapies: A Systematic Review of the Approved Active Substances for Personalized Medicine in GermanyEconomic Evaluation of Pharmacogenetic Tests in Patients Subjected to Renal Transplantation: A Review of LiteratureAdaptive capabilities and fitness consequences associated with pollution exposure in fishRecommendations for Optimizing Tuberculosis Treatment: Therapeutic Drug Monitoring, Pharmacogenetics, and Nutritional Status ConsiderationsPharmacogenetics, pharmacogenomics and ayurgenomics for personalized medicine: a paradigm shiftAn ontology-based, mobile-optimized system for pharmacogenomic decision support at the point-of-careePGA: A Web-Based Information System for Translational PharmacogenomicsA Novel Drug-Mouse Phenotypic Similarity Method Detects Molecular Determinants of Drug EffectsGenome Sequence Variability Predicts Drug Precautions and Withdrawals from the MarketXenobiotic Metabolism and Gut MicrobiomesStructural characterization of single nucleotide variants at ligand binding sites and enzyme active sites of human proteinsDifferences in the origin of philosophy between Chinese medicine and Western medicine: Exploration of the holistic advantages of Chinese medicine.Impact of germline and somatic missense variations on drug binding sitesGenome-wide data reveal novel genes for methotrexate response in a large cohort of juvenile idiopathic arthritis casesPatient Characteristics are not Associated with Clinically Important Differential Response to Dapagliflozin: a Staged Analysis of Phase 3 Data.The Genotype-Tissue Expression (GTEx) Project: Linking Clinical Data with Molecular Analysis to Advance Personalized Medicine.Cypiripi: exact genotyping of CYP2D6 using high-throughput sequencing data.Updates on drug-target network; facilitating polypharmacology and data integration by growth of DrugBank database.Effect of GSTP1 and ABCC4 gene polymorphisms on response and toxicity of cyclophosphamide-epirubicin-5-fluorouracil-based chemotherapy in Bangladeshi breast cancer patients.Increased genetic diversity of ADME genes in African Americans compared with their putative ancestral source populations and implications for pharmacogenomics.Gene co-expression network analysis identifies porcine genes associated with variation in metabolizing fenbendazole and flunixin meglumine in the liver.Nature, Nurture, and ExpertiseDeciphering next-generation pharmacogenomics: an information technology perspective.Pharmaco-metabolomics: an emerging "omics" tool for the personalization of anticancer treatments and identification of new valuable therapeutic targets.A systematic comparison and evaluation of high density exon arrays and RNA-seq technology used to unravel the peripheral blood transcriptome of sickle cell disease.Microbial determinants of biochemical individuality and their impact on toxicology and pharmacology.Whole brain approaches for identification of microstructural abnormalities in individual patients: comparison of techniques applied to mild traumatic brain injuryHow informative is the mouse for human gut microbiota research?Cometabolism of microbes and host: implications for drug metabolism and drug-induced toxicity.Lifestyle factors, medication use and risk for ischaemic heart disease hospitalisation: a longitudinal population-based study.Evolutionary Diagnosis of non-synonymous variants involved in differential drug response.Distribution of the most Common Genetic Variants Associated with a Variable Drug Response in the Population of the Republic of Macedonia.Genetics and tailored therapy in cardiovascular disease
P2860
Q24282581-619E0275-E032-4E1C-8842-778DB83F9EA5Q24600166-8CBC283D-1BF4-4107-8473-DC9E9BFA5641Q26748481-5C7B6969-1075-4E68-BB6B-27EEB96B7B25Q26852592-84A791C8-FCCE-4889-899A-8BF604FC89BEQ26864747-12146252-D999-4C11-9013-EF91E6825A01Q27692687-049242FB-DC03-4C74-A054-C849F222F387Q28070574-AD061D15-BF58-4541-9F4B-DBDB8FE233C7Q28072203-4AC04343-B09C-42BA-B327-2A2DF05FB93DQ28073025-02289CF3-285B-4ED6-8343-BD901C09D8CBQ28078890-4753FDE7-5B09-43D2-98F3-D3C9C4394A30Q28079207-08B99DC8-58AF-48CD-82BC-309C02BA7971Q28088445-9FFF1C8F-091D-42B3-A76E-E4A354FC5871Q28538389-6EE2555A-C152-4641-BFB0-AFD7A966EA92Q28554117-ADF7C461-53C2-4595-A883-935C66630FDCQ28554371-7CC8D83F-6551-49C1-92EA-4476BF3B3A18Q28554426-D33ECCB6-68A4-4745-8753-7A1D43D158EDQ28554445-95B9F059-F933-44FA-A213-0BC6784E101EQ28828464-E86986D7-9B1C-41E9-924B-00DDD09E8949Q30353144-F1124456-025F-4BC6-99B9-CCCD27333F6CQ30383865-68DA61D5-138B-457A-8CB9-62C059879C9BQ30795448-16AC72BC-3FBA-435D-A1DC-71FFD9B8BFDEQ30877953-1F3BB06A-A950-4125-A8F0-5B7DFAD10280Q30916493-AE65D586-C037-48A1-805A-10842E0793BAQ30971296-C8C50646-D1C9-4E90-9AD5-81110F7253FEQ31009476-F561D730-CDE1-4357-843C-7AC8031FDFCDQ33420396-6EB3C641-46A2-45C2-82E4-5BF0B2F5B204Q33613526-4CED871E-D754-4496-BFAB-FDE591006EE7Q33683604-5ACBC5FE-9C53-4B67-82AA-252D599A988AQ33759731-E04497DE-E40A-4D14-9EEA-00C1DA184C58Q33987606-1893318D-4F38-4E1C-94E1-B35F688384BEQ34234941-9F0711CA-CA03-482E-9CB0-95B15922F37FQ34322438-C3C125D5-8EA1-4208-A25A-B14E11CB5455Q34615534-4DEFA6FC-53D8-4832-A71B-621F255381C5Q34651200-9874684A-50AB-44F7-A763-C56DAB44578FQ34818253-C346B968-F1D6-4447-AA89-2191D56F6720Q34915414-A57D774D-C3EB-477D-9B70-0A70296E2CC1Q35023454-CAC1168C-D45F-4F3E-8ED5-5CCF577E6F44Q35043079-99D20762-ED82-4D7D-A7F6-F5E3C12DE1CDQ35549639-A8920D83-F6CD-4BE3-B9D0-401AD053EA80Q35638586-CD0C7CF0-FAFB-4A83-BF95-175AE23AEE95
P2860
Pharmacogenetics, pharmacogenomics, and individualized medicine
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Pharmacogenetics, Pharmacogenomics, and Individualized Medicine
@nl
Pharmacogenetics, pharmacogenomics, and individualized medicine
@ast
Pharmacogenetics, pharmacogenomics, and individualized medicine
@en
Pharmacogenetics, pharmacogenomics, and individualized medicine
@en-gb
type
label
Pharmacogenetics, Pharmacogenomics, and Individualized Medicine
@nl
Pharmacogenetics, pharmacogenomics, and individualized medicine
@ast
Pharmacogenetics, pharmacogenomics, and individualized medicine
@en
Pharmacogenetics, pharmacogenomics, and individualized medicine
@en-gb
prefLabel
Pharmacogenetics, Pharmacogenomics, and Individualized Medicine
@nl
Pharmacogenetics, pharmacogenomics, and individualized medicine
@ast
Pharmacogenetics, pharmacogenomics, and individualized medicine
@en
Pharmacogenetics, pharmacogenomics, and individualized medicine
@en-gb
P921
P3181
P356
P1476
Pharmacogenetics, pharmacogenomics, and individualized medicine
@en
P2093
A. Y. H. Lu
P2880
P304
P3181
P356
10.1124/PR.110.003533
P50
P577
2011-03-24T00:00:00Z